Try Claude
Lead FinderFind & enrich companies and people
AI Tools for Geneticists
AI tools that help geneticists search the scientific literature, find clinical trials for gene therapies, look up drug information for genetic conditions, generate molecular diagrams, and compile research reports.
Get started for free
Works in Chat, Cowork and Code
Title (abbreviated)JournalYear
Adenine base editing corrects pathogenic SNVs in vivoNature2022
High-fidelity ABE variants minimize off-target RNA editsNat Biotechnol2022
Base editing of haematopoietic stem cells for sickle cellNature2023
CBE evolution: reducing bystander edits with new deaminasesCell2021
22 papers found · sorted by citation count
Genetics and genomics literature search
Search millions of peer-reviewed genetics papers across classical genetics, molecular genetics, genomics, epigenetics, and population genetics. Build comprehensive reference lists for grant applications, review articles, and study design.
Find the top papers on long-read sequencing methods for detecting structural variants in cancer genomes published since 2021, sorted by citations.
Found 19 papers. Top result: "Long-read sequencing reveals complex structural variants in cancer" (Nature Genetics, 2022, 441 citations). Returns DOI, journal, SV types detected, and comparison to short-read benchmarks for each paper.
ToolRouter search_papers
Title (abbreviated)JournalYear
Long-read sequencing reveals complex SVs in cancerNat Genetics2022
Oxford Nanopore detects complex rearrangements missed by WGSGenome Res2022
PacBio SMRT identifies cryptic fusion genes in AMLLeukemia2023
19 papers found
Gene therapy clinical trials monitoring
Track the rapidly evolving gene therapy pipeline on ClinicalTrials.gov. Find recruiting trials for specific genetic conditions, monitor competitor programs, and identify patient referral opportunities for rare disease research.
Find Phase 2 and Phase 3 gene therapy trials for inherited retinal diseases recruiting in the US or Europe.
Found 11 recruiting trials. Notable: AAV2-RPE65 long-term follow-up (Phase 3, 6 sites), CPCB-RPE1 patch for Stargardt (Phase 2/3), and a novel CRISPR-CEP290 in vivo edit for LCA10 (Phase 2, first dosed Jan 2024). Includes NCT numbers and eligibility summaries.
ToolRouter search_trials
NctConditionApproach
NCT00999609LCA2 (RPE65)AAV2-RPE65 long-term follow-up
NCT04745741Stargardt'sCPCB-RPE1 patch
NCT03872479LCA10 (CEP290)CRISPR in vivo edit
11 recruiting trials · ClinicalTrials.gov
Genetic condition drug information
Look up FDA-approved treatments for genetic conditions including gene therapies, enzyme replacement therapies, substrate reduction therapies, and mRNA medicines. Retrieve mechanism, dosage, efficacy data, and safety profiles for pharmacological reviews.
Get FDA labeling for patisiran (Onpattro) including mechanism of action, indicated condition, dosage, and key clinical trial efficacy data.
Patisiran: siRNA targeting TTR mRNA, indicated for hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. Dosage: 0.3 mg/kg IV q3 weeks. In APOLLO trial: 56% reduction in modified NIS+7 vs placebo (p<0.001). Premedication required.
ToolRouter search_drug
Mechanism
siRNA targeting TTR mRNA — RNAi-mediated knockdown
Indication
Hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy
Dosage
0.3 mg/kg IV q3 weeks — premedication required
APOLLO efficacy
56% reduction in modified NIS+7 vs placebo (p<0.001)
Molecular genetics diagrams
Generate labeled diagrams of DNA repair pathways, gene editing mechanisms, genomic structural elements, and inheritance patterns. Create publication-quality visuals for papers, grant applications, and educational presentations.
Draw a diagram showing the different classes of CRISPR systems (Class 1 and Class 2) and their signature effector proteins with examples.
Generated classification diagram: Class 1 (multi-subunit effectors) → Type I (Cascade-Cas3), Type III (Cmr/Csm complexes), Type IV. Class 2 (single-protein effectors) → Type II (Cas9), Type V (Cas12a/b), Type VI (Cas13). Includes PAM requirements and nucleic acid targets for each.
ToolRouter render_diagram
Class 1 (multi-subunit)
Type I (Cascade-Cas3), Type III (Cmr/Csm), Type IV
Class 2 (single-protein)
Type II (Cas9), Type V (Cas12a/b), Type VI (Cas13)
PAM annotations
Requirements and nucleic acid targets labeled per type
Deep research on genomics topics
Compile multi-source research reports on any genetics or genomics topic — from GWAS findings to gene therapy safety profiles. Pull together the evidence base quickly for proposals, review articles, and clinical briefings.
Compile a research report on the therapeutic potential and safety landscape of in vivo CRISPR editing using lipid nanoparticle delivery in the liver.
Compiled 26-source report: LNP delivery to liver well-established (Intellia NTLA-2001 Phase 1 results: sustained TTR knockdown >95%); key safety considerations include off-target editing monitoring, innate immune response to LNPs, and long-term durability data; prime editing programs entering IND-enabling studies.
ToolRouter research
Delivery
LNP liver delivery well-established — Intellia NTLA-2001 Phase 1: >95% sustained TTR knockdown
Off-target monitoring
GUIDE-seq / DISCOVER-seq required for IND packages
Innate immune response
LNP immunogenicity remains key safety consideration
Prime editing
IND-enabling studies underway — next wave programs
Research grant discovery for genetics
Find NIH NHGRI, NCI, NIDDK, and private foundation funding for genetics and genomics research. Filter by disease area, career stage, and submission deadline.
Find NIH grants for geneticists studying rare monogenic disorders and gene therapy approaches, with deadlines in the next 90 days.
Found 7 opportunities: NHGRI R01 Rare Disease Genomics (April 5, up to $2.5M/5yr), NCATS Rare Diseases Clinical Research Network (rolling, consortium), Muscular Dystrophy Association Research Grant (March 31, up to $300K/3yr). Includes FOA numbers and eligibility details.
ToolRouter search_grants
GrantInstituteMax award
R01 Rare Disease GenomicsNHGRI$2.5M/5yr
NCATS Rare Diseases Clinical Research NetworkNCATSconsortium
MDA Research GrantMDA$300K/3yr
7 opportunities · include FOA numbers
Ready-to-use prompts
Literature search
Find the top 15 papers on polygenic risk scores for complex disease prediction published since 2021. Include citation counts, journals, diseases studied, and key performance metrics.
Gene therapy trial search
Find Phase 1 and Phase 2 gene therapy trials for sickle cell disease and beta-thalassemia recruiting in 2024-2025. Include sponsor, approach (gene addition vs editing), and enrollment status.
Drug info lookup
Get FDA labeling for voretigene neparvovec (Luxturna) gene therapy including delivery vector, dosage, indication, and long-term efficacy data from pivotal trials.
Inheritance diagram
Draw an autosomal recessive inheritance pedigree diagram for a hypothetical family showing carrier parents and affected, carrier, and unaffected offspring across two generations.
Research synthesis
Research the current state of epigenome editing tools — CRISPR-dCas9 fusions for methylation writing/erasing, published therapeutic targets, and key challenges in specificity.
Grant search
Find NIH NHGRI and private foundation grants for early-career geneticists studying human population genomics or rare variant discovery. Include deadlines and award amounts.
Find collaborators
Find genomics researchers and clinical geneticists at major academic medical centers in the US and UK specializing in rare Mendelian disease gene discovery.
CRISPR mechanism diagram
Draw a step-by-step diagram of SpCas9-mediated genome editing showing guide RNA design, R-loop formation, PAM recognition, cleavage, and DNA repair outcomes.
Tools to power your best work
Academic ResearchSearch papers, authors, citations
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Diagram GeneratorRender Mermaid, PlantUML & more
Chemistry LookupCompounds, elements, and safety
Clinical TrialsClinical trials & drug safety data
Grants FinderFind grants, funding fits, and precedent
165+ tools.
One conversation.
Everything geneticists need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Gene therapy development landscape review
Before starting a new program or proposal, comprehensively map the clinical, regulatory, and scientific landscape for a target disease or gene.
Grant proposal preparation
Build a compelling genetics grant application with a deep literature review, clear research gap, and mechanistic diagrams.
Rare disease research orientation
When starting work on a new rare genetic condition, rapidly build an evidence base covering genetics, natural history, and therapeutic approaches.
Frequently Asked Questions
Does Clinical Trials cover gene therapy IND-stage studies?
Clinical Trials searches ClinicalTrials.gov, which covers registered studies from Phase 1 onwards. IND-enabling preclinical work is not included. Studies are required to register before first patient enrollment, so Phase 1 gene therapy trials appear as soon as they begin recruiting.
Can Drug Information cover approved gene therapies like Casgevy or Luxturna?
Yes. Drug Information covers the FDA drug labeling database, which includes approved gene and cell therapies. For recently approved products, the most current labeling is retrieved.
Can Academic Research find papers on population genomics and GWAS studies?
Academic Research covers the full scope of genetics and genomics literature including GWAS, population genetics, functional genomics, and clinical genetics. You can filter by study type, date, and keyword to target any subfield.
Is there a way to check off-target editing analysis papers?
Academic Research can search for papers on off-target analysis methods (e.g., GUIDE-seq, CIRCLE-seq, DISCOVER-seq) and their application to specific CRISPR tools. Deep Research is additionally useful for compiling comparative method performance summaries.
Are Grants Finder results specific to genomics and gene therapy funding?
Grants Finder covers all NIH institutes, so queries focused on NHGRI, NIDDK, NCATS, and disease-specific institutes (e.g., NCI for cancer genetics) will surface genomics-relevant opportunities. Private foundations like Broad Institute, Gates Foundation, and rare disease foundations are also included.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code